We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lupus Genetic Risk Variant Allelic Enhancer Activity Discovered

By LabMedica International staff writers
Posted on 31 Mar 2021
Systemic lupus erythematosus (SLE) affects about 300,000 people in the USA, the majority of whom are women. More...
Previous studies have implicated both genetic and environmental contributors to the condition. While nearly 100 genetic loci have been associated with lupus, it is also closely tied to previous infection with Epstein-Barr virus.

SLE is a complex disease that involves multiple cell types. Previous systematic studies demonstrate that SLE-risk loci are enriched for B cell-specific genes and regulatory regions. B cells are critical to the pathoetiology of SLE, a disease characterized by autoantibody production. B cells also present self-antigens to T cells in the development of an autoantigen-focused (i.e., “self”) inflammatory response.

A team of Medical Scientists at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) and their colleagues applied a gene screening tool they developed to further investigate genetic loci associated with SLE. Through their massively parallel reporter assay (MPRA) approach, they narrowed in on key disease-linked genetic variants and began to tease out disease-associated biological mechanisms.

The team first conducted linkage disequilibrium expansion analyses in different ancestral groups for the 91 risk loci to capture as many disease-linked variants as possible. In all, they identified 3,073 genetic variants, to which they added a further 20 variants highlighted in a previous study. For each of these, they generated a pair of 170-base-pair DNA oligonucleotides with random 20mers for barcoding and added the eGFR gene under a minimal promoter. In all, they generated 12,478 oligos, which they transfected into an Epstein-Barr virus-transformed B cell line.

The investigators further found that certain transcription factors had altered binding at these SLE risk loci. For instance, the rs3101018 variant, for which the non-risk allele exhibits 1.7-fold stronger enhancer activity, they uncovered 15 proteins that better bound the non-risk allele and two that preferred the risk allele. The ATF7, CREB1, and CREM proteins all bound the non-risk allele more tightly than the risk allele, suggesting that weaker binding to the risk allele could change how other proteins are recruited to the locus and affect the expression of the associated C4A gene. They similarly found changed protein binding at the rs2069235 variant. additionally transfected their SLE MRPA library into the Jurkat cell line of T cells, another key cell type in lupus. In this cell line, they uncovered 92 SLE risk variants that were allelic enhancer variants, a quarter of which were also found in the B cell line.

Leah C. Kottyan, PhD, an Associate Professor and joint senior author of the study, said, “This study not only provides several critical new discoveries about lupus, and it also provides a blueprint for dissecting the genetic mechanisms of many complex human diseases.”

The authors concluded that the MPRA is a robust tool for the nomination of causal genetic risk variants for any phenotype or disease with risk loci that act through genotype-dependent gene regulatory mechanisms, with this study providing a blueprint for dissecting the genetic etiology of many complex human diseases. The study was published on March 12, 2021 in the journal Nature Communications.

Related Links:
Cincinnati Children’s Hospital Medical Center


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.